Citadel Advisors’s Inhibrx INBX Stock Holding History

Citadel Advisors’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-33,157	Closed	-$3.32M	–	14249
2026 Q1	$2.23M	Buy	33,157 +6,257	+23%	+$464K	﹤0.01%	5861
2025 Q4	$2.13M	Sell	26,900 -30,294	-53%	-$2.06M	﹤0.01%	5792
2025 Q3	$1.93M	Buy	+57,194	New	+$1.41M	﹤0.01%	6146

Other funds holding INBX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors's INBX Position: Q2 2026 in Review

Citadel Advisors sold out of Inhibrx (INBX) in Q2 2026, closing a stake of 33,157 shares — an estimated $3.32M sold.

Citadel Advisors first reported a position in INBX in Q3 2025 and held it in 3 quarters. The position peaked at $2.23M in Q1 2026. 162 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

Citadel Advisors reported no remaining Inhibrx position as of Q2 2026 after selling out during the quarter.
Citadel Advisors sold 33,157 Inhibrx shares in Q2 2026, an estimated $3.32M.
Citadel Advisors first reported a position in Inhibrx in Q3 2025 and held it in 3 quarters.
Citadel Advisors's Inhibrx position peaked at $2.23M in Q1 2026.
162 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.